Efficacy and economics of targeted panel versus whole exome sequencing in 878 patients with suspected primary immunodeficiency

BACKGROUND: NGS has become a first-line tool for diagnosis of PID. However, patient access remains limited due to restricted insurance coverage and a lack of guidelines addressing use of targeted panels vs WES. OBJECTIVES: To compare targeted next generation sequencing (NGS) with whole exome sequenc...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:J Allergy Clin Immunol
Egile Nagusiak: Platt, Craig D., Zaman, Fatima, Bainter, Wayne, Stafstrom, Kelsey, Almutairi, Abuarahman, Reigle, Margot, Weeks, Sabrina, Geha, Raif S., Janet, Chou
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2020
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7870529/
https://ncbi.nlm.nih.gov/pubmed/32888943
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jaci.2020.08.022
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak